追加説明:
This industrial-grade Semaglutide (CAS 910463-68-2, C187H291N45O59), manufactured by Fujian Lumira Biotech, is a synthetic GLP-1 receptor agonist modified to resist DPP-4 degradation, extending its half-life to support once-weekly subcutaneous dosing; the supplier describes its mechanism as glucose-dependent insulin stimulation, glucagon suppression, delayed gastric emptying, and appetite reduction, and notes it is marketed globally under brand names including Ozempic, Rybelsus, and Wegovy for diabetes and weight management, with emerging evidence of cardiovascular benefit. It is distributed across North America, Europe, Asia, the Middle East, and Africa.
評価とコメントを残す